Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes.
|
14633865 |
2003 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the role of PPAR-gamma in proximal tubular cells with respect to cell growth and inflammation in diabetic nephropathy is largely unknown.
|
15113752 |
2004 |
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist.
|
16687627 |
2006 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Evidence shows that PPAR-gamma agonists also ameliorate renal fibrotic lesions in both diabetic nephropathy and nondiabetic chronic kidney disease.
|
16291834 |
2006 |
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The genetic influence of PPARG P12A genotype is modest and is overshadowed by duration of diabetes and systolic blood pressure as the major risk factors for diabetic nephropathy in the Oji-Cree population.
|
17493550 |
2007 |
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
The genetic influence of PPARG P12A genotype is modest and is overshadowed by duration of diabetes and systolic blood pressure as the major risk factors for diabetic nephropathy in the Oji-Cree population.
|
17493550 |
2007 |
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We aim to investigate Turkish type 2 diabetic patients with/without diabetic nephropathy and healthy group and examined the contribution of the G/C exon 2 and T/C exon 6 of the PPAR gamma gene polymorphism to the development of diabetic nephropathy.
|
17681394 |
2007 |
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
We examined the relationship between two PPAR-gamma gene polymorphisms, namely the P12A and C161T, and cardiovascular disease in patients with diabetic nephropathy.
|
18417957 |
2008 |
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We conclude that P12A and C161T polymorphisms of the PPAR-gamma gene are important predictors of cardiovascular event in patients with diabetic nephropathy.
|
18417957 |
2008 |
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma 2 gene is suggested to associate with diabetic nephropathy and cardiovascular disease in type 2 diabetes.
|
18467141 |
2008 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
RGD |
In the present study, we investigated the effect and molecular mechanism of the PPARgamma agonist, pioglitazone, on the progression of diabetic nephropathy in type 2 diabetic rats.
|
18388116 |
2008 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes.
|
19506043 |
2009 |
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The +A2962G of PPARGC1A and the 3 polymorphisms of PPARG were not associated with DN.
|
19900151 |
2010 |
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients.
|
19837787 |
2010 |
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that the Pro12Ala polymorphism of the PPARG gene may be associated with diabetic nephropathy among Asians.
|
22103651 |
2012 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
EGFR inhibition may be a therapeutic strategy in the treatment of diabetic nephropathy and in limiting salt and water retention, which currently restricts the use of PPARγ agonists.
|
23370527 |
2013 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate a novel mechanism that CDK5 increases tubulointerstitial fibrosis by activating the ERK1/2/PPARγ pathway and EMT in DN.
|
27145370 |
2016 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, we propose a novel role of the miR-27a-PPARγ axis in fostering the progression toward more deteriorated renal TIF in DN.
|
27351287 |
2016 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Impact of Peroxisome Proliferator-Activated Receptor Gamma and Its Interaction with Abdominal Obesity on Diabetic Nephropathy in Chinese Han.
|
28013303 |
2017 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of the present study is to identify the regulation of lncRNA TUG1 on extracellular matrix accumulation via mediating microRNA-377 targeting of PPARγ, and investigate the underlying mechanisms in progression of DN.
|
28137588 |
2017 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Herein, we asked whether miR-27a mediates podocyte injury through PPARγ/β-catenin signaling in DN.
|
28277542 |
2017 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
CTD_human |
Nephropathy in Pparg-null mice highlights PPARγ systemic activities in metabolism and in the immune system.
|
28182703 |
2017 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, in line with the role of PPARγ in metabolic homeostasis, Pparg null-mice first represent a potent model for studying the initiation and the development of diabetic nephropathy.
|
28182703 |
2017 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
To investigate this hypothesis, db/db diabetic mice were used to establish a DKD model and the PPARγ agonist rosiglitazone was employed to induce PGC‑1α expression in vivo.
|
29344670 |
2018 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
For this purpose, we performed a microarray analysis on kidneys of 3-wk-old peroxisome proliferator-activated receptor-γ (PPARγ)-null and AZIP/F1 mice, which are two models of diabetic nephropathy due to lipodystrophy.
|
29488390 |
2018 |